Tourmaline Bio, Inc.
Tourmaline Bio, Inc. (TRML) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · TRML · as of Jun 8, 2026
Key Statistics
Explore Tourmaline Bio, Inc. Data
trml stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 10 · Buy rate: 10.0%
The TRML analyst consensus is Hold, based on ratings from 10 Wall Street analysts over the past 3 months. The average 12-month price target is $48.50, representing +1.08% upside from the current price of $47.98.
Competitors & Peers
trml competitorsTRML
AMLX
DNTH
ELVN
IMTX
ORICStock Performance
Full HistoryAbout Tourmaline Bio, Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic c…
what is tourmaline bio, inc. · trml stock overview · tourmaline bio, inc. company profile · who is tourmaline bio, inc. ceo · trml NASDAQ · tourmaline bio, inc. headquarters · tourmaline bio, inc. business segments
About Stock Overview & Key Data
Tourmaline Bio, Inc. (TRML) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 7, 2021. As of the latest trading session, TRML stock price is $47.98, with a market capitalization of $1.2B. The stock has returned +86.98% over the past 12 months and +132.46% year-to-date.
According to 10 Wall Street analysts, the consensus rating for Tourmaline Bio, Inc. stock is Hold, with an average 12-month price target of $48.50. In fiscal year 2024, Tourmaline Bio, Inc. reported revenue of — and net income of -$73.2M. For detailed data — including Tourmaline Bio, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Tourmaline Bio, Inc. (TRML) stock price is $47.98. The stock is traded on NASDAQ under the ticker symbol TRML. The 52-week range is $11.56 – $48.27.